| This division is focused on offering a comprehensive product basket covering Anti-asthma and Chronic Obstructive Pulmonary Disorders (COPD). Within a short span of two years, the Company, through its Respira division has helped Lupin attain a significant size and share in the Indian anti-asthma market. The Company is currently positioned at No. 2 in the Anti-Asthma market estimated at Rs.4,592
mn. with a growth rate of 20.4%.
Key Products : Lupin Respira
|
Product |
Therapeutic segment |
Product Rank in the relevant segment |
|
L-CIN |
Levofloxacn |
1 |
|
Esiflo |
Salmeterol+Fluticasone |
2 |
|
Budamate |
Formoteral+Budesonide |
2 |
|
Budate |
Budesonide |
2 |
|
Tiomate |
Tiotropium+Formoteral |
2 |
|
Telekast |
Montelukast |
3 |
|
Salbair |
Salbutamol |
3 |
| 
